Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNYZ) Deferred Taxes (2016 - 2025)

Historic Deferred Taxes for Ligand Pharmaceuticals (LGNYZ) over the last 15 years, with Q3 2025 value amounting to -$21.3 million.

  • Ligand Pharmaceuticals' Deferred Taxes fell 117052.31% to -$21.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $579000.0, marking a year-over-year increase of 13169.13%. This contributed to the annual value of $15.8 million for FY2024, which is 23508.89% up from last year.
  • As of Q3 2025, Ligand Pharmaceuticals' Deferred Taxes stood at -$21.3 million, which was down 117052.31% from $325000.0 recorded in Q2 2025.
  • Ligand Pharmaceuticals' 5-year Deferred Taxes high stood at $20.7 million for Q2 2024, and its period low was -$46.3 million during Q4 2022.
  • In the last 5 years, Ligand Pharmaceuticals' Deferred Taxes had a median value of $325000.0 in 2025 and averaged -$1.1 million.
  • Over the last 5 years, Ligand Pharmaceuticals' Deferred Taxes had its largest YoY gain of 92270.66% in 2022, and its largest YoY loss of 1200051.41% in 2022.
  • Ligand Pharmaceuticals' Deferred Taxes (Quarter) stood at $389000.0 in 2021, then tumbled by 12000.51% to -$46.3 million in 2022, then soared by 89.34% to -$4.9 million in 2023, then skyrocketed by 357.18% to $12.7 million in 2024, then crashed by 267.68% to -$21.3 million in 2025.
  • Its last three reported values are -$21.3 million in Q3 2025, $325000.0 for Q2 2025, and $8.8 million during Q1 2025.